Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | P2RX7 | Q99572 | 10/20 | 0.45 |
| ▸ | MAPKAPK2 | P49137 | 1/20 | 0.34 |
| ▸ | LTA4H | P09960 | 1/20 | 0.32 |
| ▸ | IL2 | P60568 | 1/20 | 0.32 |
| ▸ | CHRNA7 | P36544 | 1/20 | 0.31 |
| ▸ | CHRNA10 | Q9GZZ6 | 1/20 | 0.31 |
| ▸ | CHRNA9 | Q9UGM1 | 1/20 | 0.31 |
| ▸ | TRPM4 | Q8TD43 | 1/20 | 0.31 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.31 |
| ▸ | POLB | P06746 | 1/20 | 0.31 |
| ▸ | TTK | P33981 | 1/20 | 0.31 |
| ▸ | SCARB1 | Q8WTV0 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL5033017 | 0.85 | P2RX7 (0.41) | P2RX7MAPKAPK2LTA4HIL2 | |
| SCHEMBL5034948 | 0.78 | P2RX7 (0.52) | P2RX7LTA4HIL2TRPM4 | |
| SCHEMBL5027378 | 0.66 | IL2 (0.44) | P2RX7LTA4HIL2 | |
| SCHEMBL18930006 | 0.66 | NPC1 (0.46) | P2RX7LTA4HIL2CHRNA7CHRNA10 | |
| SCHEMBL13625433 | 0.65 | LTA4H (0.46) | LTA4HCHRNA7CHRNA10CHRNA9HSD17B10 | |
| SCHEMBL1459892 | 0.65 | NPC1 (0.44) | P2RX7LTA4HIL2CHRNA7CHRNA10 | |
| SCHEMBL5033022 | 0.65 | IL2 (0.48) | LTA4HIL2HSD17B10 | |
| SCHEMBL8232402 | 0.64 | IL2 (0.44) | P2RX7LTA4HIL2CHRNA7CHRNA10 | |
| SCHEMBL5030643 | 0.64 | CIT (0.46) | IL2 | |
| SCHEMBL5033044 | 0.64 | IL2 (0.42) | P2RX7LTA4HIL2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20140121217-A1 | SUBSTITUTED BIARYL COMPOUNDS FOR INFLAMMATION AND IMMUNE-RELATED USES | SYNTA PHARMACEUTICALS CORP. (US) | 2014-05-01 | — | — | US | disclosed |
| US-8623871-B2 | Substituted biaryl compounds for inflammation and immune-related uses | SYNTA PHARMACEUTICALS CORP. (US) | 2014-01-07 | — | — | US | disclosed |
| EP-1998612-A2 | SUBSTITUTED BIARYL COMPOUNDS FOR INFLAMMATION AND IMMUNE-RELATED USES | Synta Pharmaceuticals Corporation (US) | 2008-12-10 | — | — | EP | disclosed |
| US-20070254363-A1 | Substituted biaryl compounds for inflammation and immune-related uses | SYNTA PHARMACEUTICALS CORP. (US) | 2007-11-01 | — | — | US | disclosed |
| WO-2007087442-A2 | SUBSTITUTED BIARYL COMPOUNDS FOR INFLAMMATION AND IMMUNE-RELATED USES | SYNTA PHARMACEUTICALS CORP. (US) | 2007-08-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070254363-A1 | Substituted biaryl compounds for inflammation and immune-related uses | CCR1, CCR3, CXCR2 | P2RX7 257/4885MAPKAPK2 2813/4885LTA4H 122/4885 |
| US-20140121217-A1 | SUBSTITUTED BIARYL COMPOUNDS FOR INFLAMMATION AND IMMUNE-RELATED USES | CCR1, CCR3, CXCR2 | P2RX7 257/4885MAPKAPK2 2813/4885LTA4H 122/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.